Acurx announces filing of provisional patent application for ibezapolstat to treat cdi while reducing recurrence of infection and improving the health of the gut microbiome

Staten island, n.y., july 7, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq acxp) ("acurx" or the "company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a provisional patent application in the united states patent and trademark office (uspto).
ACXP Ratings Summary
ACXP Quant Ranking